Folke Sjöqvist

Folke Sjöqvist's AcademicInfluence.com Rankings

Folke Sjöqvist

Medical

#1917

World Rank

#2302

Historical Rank

Pharmacology

#187

World Rank

#227

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Folke Sjöqvist Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Folke Sjöqvist's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. (1993) (661)
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. (1994) (459)
Relationship between Plasma Level and Therapeutic Effect of Nortriptyline (1971) (445)
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages (2001) (423)
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin (1992) (420)
Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy (1969) (361)
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. (1995) (338)
Use of doping agents, particularly anabolic steroids, in sports and society (2008) (328)
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. (1971) (324)
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. (1978) (319)
Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. (1980) (290)
Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. (1967) (280)
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. (1999) (277)
Disposition of chloroquine in man after single intravenous and oral doses. (1983) (255)
Plasma protein binding of diphenylhydantoin in man; Interaction with other drugs and the effect of temperature and plasma dilution (1970) (246)
Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. (1982) (243)
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine (1993) (240)
The 'wise list'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. (2011) (212)
Correlation of Subjective Side Effects with Plasma Concentrations of Nortriptyline (1970) (209)
E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation (1981) (198)
Drug utilization 90% – a simple method for assessing the quality of drug prescribing (1998) (192)
Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population (1992) (192)
Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype (2002) (191)
Effect of environmental factors on drug metabolism: Decreased plasma half‐life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides (1969) (190)
Plasma protein binding of tricyclic anti-depressants in man. (1969) (169)
The presence of a monooxygenase system in human fetal liver microsomes. (1970) (155)
Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype (1991) (154)
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin (1985) (152)
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. (1989) (147)
Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression (1979) (142)
Clinical Pharmacology in Psychiatry (1981) (138)
Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. (1997) (136)
New possibilities for adrenergic modulation of ganglionic transmission. (1966) (131)
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. (1980) (120)
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro (2001) (118)
The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology (2003) (118)
Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. (1989) (115)
Psychotropic Drugs (2) Interaction between Monoamine Oxidase (MAO) Inhibitors and other Substances (1965) (114)
Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline. (1979) (110)
Hypothermic effect of apomorphine in the mouse (1972) (104)
Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. (1971) (104)
Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. (1995) (103)
Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes (1984) (102)
Determination of bioavailability of diazepam in various formulations from steady state plasma concentration data (1972) (100)
Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. (1985) (100)
SLOW HYDROXYLATION OF NORTRIPTYLINE AND CONCOMITANT POOR DEBRISOQUINE HYDROXYLATION: CLINICAL IMPLICATIONS (1981) (95)
Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. (2010) (94)
Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. (1995) (93)
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol (1996) (92)
Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. (2009) (92)
Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers (1986) (91)
Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations. (1971) (90)
HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATION (1982) (89)
Pharmacokinetics of nortriptyline and its 10‐hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes (1998) (88)
Oxotremorine and central monoamine neurons. (1967) (82)
Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation (1983) (80)
Abnormal pharmacokinetics of phenytoin in a patient with uraemia. (1970) (80)
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients (2000) (77)
A comparative study of the metabolism of desmethylimipramine, nortriptyline, and oxyphenylbutazone in man (1969) (77)
Acetylation of procaine amide in man studied with a new gas chromatographic method. (1974) (68)
Antidepressants and drug‐metabolizing enzymes — expert group report (1996) (67)
The Correlation between the Occurrence and Localization of Acetylcholinesterase‐rich Cell Bodies in the Stellate Ganglion and the Outflow of Cholinergic Sweat Secretory Fibres to the Fore Paw of the Cat (1963) (67)
Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. (1995) (66)
[In vitro activity of chloroquine, two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum]. (1986) (65)
Enantioselective Analysis of Chloroquine and Desethylchloroquine after Oral Administration of Racemic Chloroquine (1986) (65)
CYP2D6 and CYP2C19 genotypes in an elderly Swedish population (1998) (63)
Interindividual differences in amitriptyline demethylation (1980) (63)
Interindividual differences in drug oxidation: clinical importance. (1973) (62)
Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. (2000) (61)
Characterization of chloroquine plasma protein binding in man. (1983) (61)
Protein binding of chloroquine enantiomers and desethylchloroquine. (1986) (60)
Acute effects of diphenylhydantoin in relation to plasma levels: Behavioural and psychophysiological studies (1972) (60)
DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESE (1989) (59)
The Use of Therapeutic Drug Monitoring Data to Document Kinetic Drug Interactions: An Example with Amitriptyline and Nortriptyline (1994) (59)
Micromethod for the determination of diphenylhydantoin in plasma and cerebrospinal fluid--a comparison between a gas chromatographic and a spectrophotometric method. (1972) (58)
Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine (2004) (56)
Determination of chloroquine and its desethyl metabolite in whole blood: an application for samples collected in capillary tubes and dried on filter paper. (1985) (56)
A pharmacokinetic approach to the treatment of depression. (1971) (55)
Hydroxylation of desmethylimipramine: Dependence on the debrisoquin hydroxylation phenotype (1987) (55)
The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. (1987) (54)
The role of plasma protein binding in the inhibitory effect of nortriptyline on the neuronal uptake of norepinephrine (1970) (53)
Phenytoin Excretion in Human Breast Milk and Plasma Levels in Nursed Infants (1982) (53)
High incidence of a concentration-dependent skin reaction in children treated with phenytoin. (1978) (53)
A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. (1991) (52)
The Convergence of Conventional Therapeutic Drug Monitoring and Pharmacogenetic Testing in Personalized Medicine: Focus on Antidepressants (2007) (52)
Drug metabolism in the human fetus and newborn infant. (1972) (51)
INDIVIDUAL DIFFERENCES IN THE PHARMACOKINETICS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS: ROLE OF GENETIC AND ENVIRONMENTAL FACTORS AND CLINICAL IMPORTANCE * (1971) (49)
Cholinacetylase in innervated and denervated sympathetic ganglia and ganglion cells of the cat. (1967) (49)
Decreased plasma protein binding of phenytoin in patients on valproic acid. (1979) (48)
Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism (1984) (46)
Measurement of drug utilization in Sweden: methodological and clinical implications. (2009) (46)
Two-Fold Interindividual Variation in Plasma Protein Binding of Phenytoin in Patients with Epilepsy (1976) (43)
Monitoring Tricyclic Antidepressants (1980) (42)
Drug and Therapeutics committees:a Swedish experience. (2002) (42)
Plasma disappearance of nortriptyline in a newborn infant following placental transfer from an intoxicated mother: evidence for drug metabolism. (1972) (41)
Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer. (1992) (38)
Depot Haloperidol Treatment in Outpatients With Schizophrenia on Monotherapy: Impact of CYP2D6 Polymorphism on Pharmacokinetics and Treatment Outcome (2007) (38)
Pharmacokinetics and biological effects of nortriptyline in man. (2009) (38)
PROBLEM-ORIENTED DRUG INFORMATION: A CLINICAL PHARMACOLOGICAL SERVICE (1983) (37)
[The effect of desmethylimipramine and other "anti-tremorine" drugs on the metabolism of tremorine and oxotremorine in rats and mice]. (1968) (36)
CORRELATED STUDIES OF MONOAMINES AND ACETYLCHOLINESTERASE IN SYMPATHETIC GANGLIA, ILLUSTRATING THE DISTRIBUTION OF ADRENERGIC AND CHOLINERGIC NEURONS* (1965) (36)
Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects (1984) (35)
Effect of exposure to lindane on drug metabolism: decreased hexobarbital sleeping-times and increased antipyrine disappearance rate in rats. (1971) (34)
Clinical pharmacology of antidepressant drugs: pharmacogenetics. (1984) (33)
Chloroquine and desethylchloroquine in plasma, serum, and whole blood: problems in assay and handling of samples. (1985) (33)
The hypnotic efficacy of doxylamine (1967) (32)
Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS). (1970) (32)
Relationship of N‐demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism (1984) (31)
Species differences in the plasma protein binding of desipramine (1968) (31)
The pH‐dependent excretion of mono methylated tricyclic antidepressants; In dog and man (1969) (31)
Oxazepam disposition in uremic patients. (1977) (31)
The measurement of drug consumption (1975) (30)
Plasma concentrations of 5‐(4‐hydroxyphenyl)‐5‐phenylhydantoin in phenytoin‐treated patients (1977) (30)
Drug interaction: decreased serum concentrations of rifampicin when given with P.A.S. (1971) (28)
Cholinesterase activity in innervated and denervated sympathetic ganglion cells of the cat. (1967) (27)
Prolongation and potentiation of oxotremorine effects by desmethylimipramine an "anti-tremorine" drug. (1965) (27)
The past, present and future of clinical pharmacology (1999) (26)
Drug use in Estonia in 1994–1995: a follow-up from 1989 and comparison with two Nordic countries (1998) (25)
Clinical pharmacology and the provision of drug information (2004) (25)
The use of antidepressants and therapeutic drug monitoring by general practitioners and psychiatrists: findings from a questionnaire survey in two Swedish areas. (1996) (24)
Interindividual differences in chlorthalidone concentration in plasma and red cells of man after single and multiple doses (1976) (24)
Pharmacological analysis of acetylcholinesterase-rich ganglion cells in the lumbo-sacral sympathetic system of the cat. (1963) (24)
Clinical pharmacology and primary health care in Europe — a gap to bridge (2004) (23)
Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation. (1986) (23)
Rate of metabolism of tremorine and oxotremorine in rats and mice. (1968) (22)
Gas chromatographic determination of ethosuximide and phensuximide in plasma and urine of man (1973) (22)
Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. (2001) (22)
Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors. (1984) (21)
Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients. (1979) (21)
Pharmacological properties of γ-aminobutyrylcholine a supposed inhibitory neutrotransmitter (1960) (20)
Tyramine pressor effects in man before and during treatment with nortriptyline or ECT: Correlation between plasma level and effect of nortriptyline (1970) (20)
HYDROXYLATION OF DEBRISOQUINE IN PATIENTS WITH LACTICACIDOSIS AFTER PHENFORMIN (1981) (20)
The metabolism of tremorine. Identification of a new biologically active metabolite, N-(4-pyrrolidino-2-2-butynyl)-gamma-aminobutyric acid. (1968) (20)
Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity. (1994) (20)
Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers (1974) (19)
Nonstereoselective disposition of ethosuximide in humans. (1990) (19)
Debrisoquine and S -mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia (1997) (18)
Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes (2004) (18)
Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy (1976) (18)
The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin (1987) (18)
Determination of metrifonate and dichlorvos in whole blood using gas chromatography and gas chromatography-mass spectrometry. (1990) (17)
On the role of plasma level monitoring of tricyclic antidepressants in clinical practice. (1978) (17)
No association between familial Alzheimer disease and cytochrome P450 polymorphisms. (1998) (17)
Distribution of chloroquine in human blood fractions. (1988) (17)
Development of clinical pharmacology as a medical speciality in Europe - the roles of WHO, IUPHAR and EACPT. (2014) (17)
Therapeutic traditions in Northern Ireland, Norway and Sweden: II. Hypertension (1986) (17)
Drug safety in relation to efficacy: the view of a clinical pharmacologist. (2000) (17)
Clinical pharmacology in Europe: An indispensible part of the health service (1988) (17)
Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population. (1996) (17)
Concentrations of chloroquine and desethylchloroquine in capillary blood dried on filter paper during and after treatment of Tanzanian children infected with Plasmodium falciparum. (1986) (16)
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden (2004) (16)
Genetic control of nortriptyline kinetics in man--a study of relatives of propositi with high plasma concentration. (1971) (14)
Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians. (1993) (14)
Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man (1976) (14)
Measurement of diphenylhydantoin in 0.1-ml plasma samples: gas chromatography and radioimmunoassay compared. (1976) (14)
Aging and drug disposition--metabolism. (1983) (14)
Ultrafiltration compared with equilibrium dialysis in the determination of unbound phenytoin in plasma. (1985) (13)
Decreased distribution of oxotremorine to brain after pharmacological blockade of its peripheral acetylcholine‐like effects (1971) (13)
Doses and dosage intervals of drugs—clinical practice and pharmacokinetic principles (1978) (13)
The effect of immunosympathectomy on the retention and metabolism of noradrenaline. (1967) (13)
Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19) (1999) (12)
The influence of body temperature on the elimination of oxotremorine in the mouse. (1968) (12)
Uptake and metabolism of d,1-norepinephrine-7H3 in tissues of immunosympathectomized mice and rats. (1965) (12)
Steady-state plasma concentrations of alprenolol in man (1974) (12)
Nortriptyline formation after single oral and intramuscular doses of amitriptyline (1982) (12)
Metabolism of desmethylimipramine in human foetal and adult liver microsomes. (2009) (12)
The inhibitory effect of hydrocortisone and testosterone on the plasma disappearance of nortriptyline in the dog and the perfused rat liver. (1970) (11)
Workplace drug testing (WDT) likely to increase in Europe (2000) (11)
Drug-induced changes in brain levels of oxotremorine in mice. (1968) (11)
Cytochrome P-450 in human fetal liver microsomes. (1971) (11)
Polymorphic 2-hydroxylation of desipramine (1993) (11)
The pH-dependent excretion of monomethylated tricyclic antidepressants. (1969) (10)
Effect of simultaneous treatment with low doses of perphenazine on plasma and urine concentrations of nortriptyline and 10-hydroxynortriptyline (1977) (10)
Clinical pharmacology in Stockholm 50 years—report from the jubilee symposium (2018) (10)
Treatment of depression with E-10-hydroxynortriptyline — a pilot study on biochemical effects and pharmacokinetics (2005) (9)
Circulatory effects in man of nortriptyline, a tricyclic antidepressant drug (1970) (9)
Historical perspectives: drug interactions – it all began with cheese (2010) (9)
Plasma protein binding of propranolol in disease states [proceedings]. (1977) (9)
[Biological availability--a comparison between 3 phenytoin preparations]. (1975) (9)
The Use of TDM Data to Assess the Validity of Defined Daily Doses of Antiepileptics: A Comparison Between a Czech and Swedish University Hospital (2006) (9)
The metabolism of tremorine--the identification of 1,4-di (2-oxopyrrolidino)-2-butyne (symmetric dioxotremorine). (1969) (9)
Pharmacogenetics of antidepressants. (1989) (8)
Digoxin and Phenytoin analyses as part of consultations in clinical pharmacology: a study on the use of drugs. (1981) (8)
56 Cholinesterase distribution in the sympathetic nervous system of the cat (1961) (8)
Clinical Pharmacology in European health care—outcome of a questionnaire study in 31 countries (2013) (8)
Therapeutic Monitoring of Antiepileptic Drugs: A Comparison Between a Czech and a Swedish University Hospital (2006) (8)
Morphological Correlate to a Cholinergic Sympathetic Function (1962) (7)
Prescription monitoring of drug dosages in the county of Jämtland and Sweden as a whole in 1976, 1982 and 1985 (2004) (7)
Interaction of imipramine, desmethylimipramine, nortriptyline and 1-naphthol with microsomal preparations. (1971) (7)
A quantitative approach to the initial clinical trial of tricyclic antidepressants: A comparison of Leo 640 and nortriptyline (1970) (6)
Monitoring of antidepressant drug plasma levels: the next ten years. (1979) (6)
The use of drugs in Estonia compared to the Nordic countries (2004) (6)
In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum. (1986) (6)
Plasma concentrations of diphenylhydantoin in young infants (1970) (6)
Acetylation of procaine amide in man. A preliminary communication (2004) (6)
Excessively growing monoamine-containing nerves in mice during treatment with a nerve growth factor (NGF). (1967) (5)
Interindividual andinterethnic differences inthedemethylation andglucuronidation ofcodeine (1989) (5)
Use of digoxin in a low density population area in Sweden (2004) (5)
DEBRISOQUINE PHENOTYPE AND GENOTYPE IN CHINESE (1989) (5)
Clinical pharmacology in europe (2004) (5)
Studies on the metabolism and pharamcokinetics of nortriptyline and desmethylimipramine in man. (1971) (5)
Drug dosage in the elderly — Theory and practice (1979) (4)
European Journal of Clinical Pharmacology becomes the official organ of European Association for Clinical Pharmacology and Therapeutics (1995) (4)
Relation between drug elimination kinetics in intact animals and isolated perfused liver systems: phenylbutazone (1970) (4)
[Genotyping for drug metabolism capacity can give valuable clinical information]. (1992) (4)
Pharmacological principles in the management of accidential poisoning. (1970) (4)
[Quality assurance of drug prescription in primary health care. A new database software makes the drug therapy surveillance easier]. (2001) (4)
Monoamine metabolites in cerebrospinal fluid during treatment with clonidine or alprenolol (1977) (4)
Pharmacokinetic interactions between the tuberculostatics rifampicin, para-aminosalicylic acid and isoniazid. (1970) (4)
Attitudes to development of drug therapy in Scandinavia. (1986) (4)
Beta-blocking effect and pharmacokinetics of pindolol in young and elderly hypertensive patients (2004) (4)
Stereospecific 10-hydroxylation of nortriptyline — genetic aspects and importance for biochemical and clinical effects (1983) (4)
Methodological commentary on the analysis of metrifonate and dichlorvos in biological samples. (1993) (3)
Merck fellowships contribute to the continued growth of clinical pharmacology in Sweden (2007) (3)
Uptake of3H-noradrenaline by adrenergic nerves of rat iris incubated in plasma from patients treated with various psychotropic drugs (1972) (3)
Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects (1987) (2)
[Clinical pharmacology of carbamazepine--a comparison with phenytoin]. (1985) (2)
In vitro assessment of hepatic drug metabolism in man: a clinical pharmacological perspective (1982) (2)
Mutations of the CYP2C9 gene and the response to warfarin. (2001) (2)
[Drug interaction: lethal interaction between nialamide and blue-veined cheese]. (1969) (2)
Monoamine metabolites in cerebrospinal fluid during treatment of hypertension with prazosin (1980) (2)
The future of clinical pharmacology — Rebuttal of an editor's headache (1982) (1)
Polymorphisms in drug metabolism: implications for drug utilization. (1984) (1)
[The Institute for Medical Education. The special teaching function of the Karolinska Institute]. (1993) (1)
Genetic Variability in Man as a Complicating Factor in the Extrapolation of Toxicological Data from Animals (1982) (1)
[Inter-individual differences in pharmacokinetics in humans: clinical importance]. (1973) (1)
Clinical pharmacology and primary health care in Europe--a gap to bridge. The WHO Working Group on Clinical Pharmacology in Europe. (1990) (1)
[More stringent requirements in connection with the choice of drugs. Members of the drug committees in Stockholm deliver an annual declaration of challengeability]. (2001) (1)
[Doping - a medical and ethical problem]. (1982) (1)
Metabolism of various drugs in subjects with different debrisoquine and sparteine oxidation phenotypes (1982) (1)
[Pharmacology at the start of a new millennium. Larger assortment and individual drug dosing are coming]. (2001) (1)
INTERETHNIC DIFFERENCES IN DRUG OXIDATION. IMPLICATIONS FOR THE UTILIZATION OF ANTIDEPRESSANTS AND NEUROLEPTICS (1992) (1)
PHARMACOL THER 1990;48:496-502.) (1990) (1)
The measurement of psychotherapeutic drug concentrations in biological fluids: utility in clinical trials and practice. Overview by drug classes--clinical monitoring of tricyclic antidepressant plasma concentrations. (1980) (1)
Drug interactions. (1975) (1)
Mass fragmentography in clinical psychopharmacology. (1973) (1)
[The Anti Doping Hot-Line answers questions, educate, network, research...]. (2013) (1)
[Determination of diphenylhydantoin (DFH) in plasma in patients with epilepsy]. (1969) (1)
[Transplacental passage of drugs]. (1967) (1)
Report on the workshop “molecular basis of polymorphic drug oxidation in man”, Otzenhausen, 1983 (1984) (1)
Opening address at the 1st Congress of the European Association for Clinical Pharmacology and Therapeutics. (1996) (1)
Active metabolites of antidepressants: novel aspects of hydroxylation and demethylation in man (1981) (1)
Bioavailability of chloroquine in mice infected with the intestinal trematode Echinostoma revolutum. (2009) (1)
Invitro activity ofchloroquine, thetwoenantiomers of chloroquine, desethylchloroquine andpyronaridine against Plasmodium falciparum (1986) (1)
Ulcer surgery in Estonia, a consequence of drug delay? (1998) (1)
Clinical Pharmacology - current importance and future perspectives (2009) (1)
Clinical Pharmacology in European health care—outcome of a questionnaire study in 31 countries (2013) (0)
[The 1988 Olympic Games--a turning-point in the doping problem?]. (1989) (0)
[The possibility of urine examination to determine cocaine abuse among addicts]. (1982) (0)
[Species differences in the metabolism of drugs]. (1967) (0)
[Clinical trial of drugs (6): new method for the initial trial of tricyclic antidepressants]. (1970) (0)
Treatment of Depression — Pharmacokinetic and Pharmacogenetic Considerations (1984) (0)
The role of drug interactions in interindividual variability of drug metabolism in man (2004) (0)
[Arrhythmia prophylaxis with procanamide: inadequate dosage?]. (1972) (0)
[Clinical pharmacology in education--new goals and new forms]. (1979) (0)
[Differences between individuals in human pharmacokinetics. Clinical significance]. (1972) (0)
Interindividual Differences in Drug Metabolism:Clinical Implications (1986) (0)
[Blockage of tyramine induced pressure effects with tricyclic antidepressives]. (1970) (0)
[Attitude toward clinical tests of drugs--especially psychopharmaca]. (1969) (0)
[Drug clinical trials--the example with antidepressants]. (2008) (0)
Symposium Genetic Factors Influencing Drug Action (1983) (0)
1081 – EFFECTS OF CHLORIMIPRAMINE ON AMINE METABOLITES IN CEREBROSPINAL FLUID OF DEPRESSED PATIENTS - RELATIONSHIP TO INHIBITION OF SEROTONIN UPTAKE (1977) (0)
170 – DRUG UTILIZATIDN (1977) (0)
Cytochrome P450 hereditary polymorphism in old people. (1998) (0)
TDM and Pharmacogenetics of Tricyclic Antidepressants – The Original Ideas (2005) (0)
[Individual differences in pharmacokinetics in humans (clinical importance)]. (1973) (0)
[The pharmacotherapy of rheumatoid diseases (3): clinical pharmacological points of view]. (1969) (0)
Clinical pharmacology in Europe. The WHO European Task Force on Clinical Pharmacology. (1991) (0)
[Committee for Medical Ethics in the Karolinska Institute: origin and experience]. (1971) (0)
Small gender differences in Drug concentrations stored in a TDM database (2015) (0)
Interindividual differences in pharmacokinetics in man: clinical importance. (1973) (0)
Non-responders in clinical pharmacology – a commentary to a book review by D.N. Bateman (2001) (0)
EACPT 2001 in Odense was a success: now we are heading to Istanbul (2003) (0)
DECREASEDPLASMA PROTEINBINDING OF PHENYTOININPATIENTSON VALPROICACID (1979) (0)
[Interaction between the metabolism of drugs: biochemical aspects]. (1968) (0)
Farewell and Hail (1990) (0)
Interindividual Differences in Drug Metabolism (1986) (0)
[Interaction of psychopharmaceutic agents and other drugs]. (1967) (0)
[Interaction between the metabolism of drugs: pharmacological aspects]. (1968) (0)
[Clinical trial of drugs (10): evaluation of drugs]. (1970) (0)
[Clinical pharmacology (7): clinical pharmacology as an educational discipline in Sweden]. (1970) (0)
Clinical pharmacology in Stockholm 50 years—report from the jubilee symposium (2018) (0)
[Medical drug information in the database Drugline]. (1989) (0)
[Genetic tests give the finishing touch to individual drug dosage]. (2003) (0)
[Treatment of acute poisoning. 3. Pharmacokinetic treatment principals]. (1971) (0)
[Side-effects of psychopharmaca]. (1967) (0)
Therapeutic Drug Monitoring Data—A Valuable Source for Drug Utilization Analysis (2017) (0)
Uptake of 3H-noradrenaline (3H-NA) in plasma from patients treated with thymoleptic or neuroleptic drugs. (1970) (0)
[Pharmacogenetic and interaction-model with some usual antitubercular agents]. (1970) (0)
CHARACTERIZATION OFCHLOROQUINE PLASMA PROTEIN BINDINGINMAN (1983) (0)
[Studies of indolamine metabolites in cerebrospinal fluid in depression]. (1972) (0)
[Nobel Prize in medicine: three share this year's Nobel Prize in medicine. Important principles in drug therapy]. (1988) (0)
Content of immunodepressor CsA in cornba, tears and blood by local administration and by oral administration in tears and blood (1992) (0)
[Clinical pharmacology: clinical pharmacokinetics in patient care]. (1970) (0)
CYP2D6– a Key Enzyme in the Metabolism of Antidepressants and Neuroleptics (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Folke Sjöqvist?

Folke Sjöqvist is affiliated with the following schools:

Karolinska Institute

Folke Sjöqvist's Academic­Influence.com Rankings

Why Is Folke Sjöqvist Influential?

Folke Sjöqvist's Published Works

Published Works

What Schools Are Affiliated With Folke Sjöqvist?

Folke Sjöqvist's AcademicInfluence.com Rankings